The Directors of RISS are Mr. Rob Anderson (Director), Ms
Elizabeth Furler (chair of RISS Industry Advisory Committee),
Dr. George Morstyn (chair RISS Expert Advisory Committee),
Ms. Jenny Morawska (CEO and Director) and Mr. Terry Slater
(Chairman).
The Board is supported by an independent Expert Advisory
Committee (REAC), which evaluates researcher access applications
and makes funding recommendations. REAC
Charter
An Industry Advisory Committee (IACR) advises on investment
strategies in various fields and areas of research infrastructure.
IACR Charter
The company is administered through the hosting services
of the Australian Red Cross Blood Services via their Transplantation
Services division.
Mr. Rob Anderson
Company Secretary
FCA, FAICD
Mr. Anderson is currently the MD of Orthogen which operates
in the field of cell therapies and is principal of Anderson
Business Consultants. Rob has many years experience consulting
to Government and industry. He has extensive commercial
and financial experience in a diverse range of industries
and business structures including as Partner (Audit and
Adivisory) Deloitte Touche Tohmatsu.
Ms. Elizabeth Furler
Chair of RISS Industry Advisory Committee
B.A (Social Work), Member of the Public Health Association
of Australia
Elizabeth has extensive experience in the Health Sector
and is currently Executive Director of TRACsa. Previous
positions include Executive Director of the MACsa, GM of
ANTA (Melbourne) CEO of RACGP, First Assistant Secretary
for the Commonwealth Health Services and Public Health Divisions
and Principal Adviser to Commonwealth Department of Human
Services and Health. Earlier positions included senior roles
with the government health sectors of SA, Tasmania and the
Commonwealth.
Dr. George Morstyn
Chair RISS Expert Advisory Committee
MB BS B Med Sci PhD FRACP MAICD
Dr Morstyn is applying his experience in Translational Medicine
in the academic commercial interface. He is on the Boards
of Cancer Trials Australia (a consortium of cancer centres),
The Royal Women’s Hospital, BIO 21, Proacta (based
in Auckland and San Diego developing cancer therapy) and
Neuprotect and is chairman of the scientific advisory Board
of Symbio (Japan based developing drugs for cancer treatment).
Dr Morstyn also advises The Walter and Eliza Hall Institute
and The John Curtain School of Medicine on commercialization.
His interest in Translational Research dates back to 1979
when he commenced a PhD with Professor Don Metcalf. Dr Morstyn
became head of the Clinical Program of the Ludwig Institute
for Cancer Research in Melbourne. He was principal investigator
of the earliest studies of G CSF, GM CSF and Il 4.
Dr Morstyn joined Amgen in 1987 as an advisor, later became
VP of Medical and Clinical Affairs, then Chief Medical Officer
and in 1999 Senior Vice President of Development.
Mr. Terry Slater
Chairman
BSc, BEc, MPH
Mr. Slater was the CEO of Australian’s Donate, the
peer body of the organ and tissue transplant organisations
in Australia. Terry was CEO of the Therapeutic Goods Administration
(TGA) for nine years and has subsequently consulted to many
organisations in Health services and semi-government bodies.
